Jamie Merchan, M.D. (IMAGE)
Caption
“These findings are encouraging and suggest we may be able to better understand which patients benefit from targeting this pathway,” said co-author of the study, Jamie Merchan, M.D., co-leader of the Translational and Clinical Oncology Research Program at Sylvester Comprehensive Cancer Center, part of University of Miami Miller School of Medicine, and director of its Phase 1 Clinical Trials Program.
Credit
Sylvester Comprehensive Cancer Center
Usage Restrictions
Us with Attribution
License
Original content